Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Depression 6Neoplasms 5Anxiety Disorders 5Melanoma 2Depressive Disorder, Major 2Pain 1Osteosarcoma 1Opioid-Related Disorders 1Neoplasm Metastasis 1Lymphoma 1Hospice 1Hematopoietic and Lymphatic System Neoplasm 1Endocrine Gland Neoplasms 1Depressive Disorder 1Caregiver Distress 1Carcinoma, Non-Small-Cell Lung 1Agnosia 1

Interventions

Morphine 6Analgesia 6nabiximols 3Pregabalin 3Oxycodone 3Fentanyl 3ziconotide 2Surveys and Questionnaires 2Saline Solution 2Radiofrequency Ablation 2Methadone 2Lidocaine 2Ketamine 2Ibandronic Acid 2Gemcitabine 2Duloxetine Hydrochloride 2Docetaxel 2Botulinum Toxins, Type A 2trimebutine 3-thiocarbamoylbenzenesulfonate 1tanezumab 1tandutinib 1siltuximab 1resiniferatoxin 1incobotulinumtoxinA 1imisopasem manganese 1fulranumab 1erenumab 1cyclobenzaprine 1caffeine, sodium benzoate drug combination 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pain × Psilocybin × Clear all
NCT00979693 2023-12-26

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Multidisciplinary Association for Psychedelic Studies

Phase 2 Withdrawn
Dermatologic

Anxiety Disorders, Depression, Melanoma, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡